Výsledky vyhledávání - "D A, Rinaldi"

A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia

Autor: T Griffin, G Medina, Manuel Hidalgo, J Turner, D D Von Hoff, D A Rinaldi

Publikováno v: Anti-Cancer Drugs. 10:393-396

This study evaluated the toxicity and efficacy of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia (CIA). Patients with breast cancer scheduled to receive FAC chemotherapy (5-fluorouracil, adriamycin a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0641287669f4b8b95902724a0a4d8726
https://doi.org/10.1097/00001813-199904000-00007

Zobrazit plný text záznamu

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion

Autor: Patrick W. Cobb, L Smith, J. G. Kuhn, Ahmad Awada, D. D. Von Hoff, J R Eckardt, D A Rinaldi, Howard A. Burris, S. Fields

Publikováno v: Anti-Cancer Drugs. 5:394-402

Topotecan (SKF 104864-A, NSC 609699) is a water-soluble, semi-synthetic analog of camptothecin which is an inhibitor of topoisomerase I. Since topoisomerase I is cell specific for S phase, we undertook a phase I study to determine the maximum tolerat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a1876d9677409b1423e04d91ef44a5
https://doi.org/10.1097/00001813-199408000-00002

Zobrazit plný text záznamu

The reticulocyte in pulmonary tuberculosis

Autor: D R, RINALDI

Publikováno v: Publicaciones. Buenos Aires (Argentina). Centro de Investigaciones Tisiologicas. 10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7c814643bc13b378005e5423157e87d5
https://pubmed.ncbi.nlm.nih.gov/20240290

Zobrazit plný text záznamu

Overview of phase I trials of multitargeted antifolate (MTA, LY231514)

Autor: D A, Rinaldi

Publikováno v: Seminars in oncology. 26(2 Suppl 6)

Multitargeted antifolate (MTA, LY231514) is a novel antifolate antimetabolite, with antitumor activity via inhibition of thymidylate synthase, glycinamide formyl transferase, and dihydrofolate reductase. Three dosing schedules have been investigated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::810eafe6015e7b80cfc62653cb3e2a8e
https://pubmed.ncbi.nlm.nih.gov/10598560

Zobrazit plný text záznamu

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea

Autor: G I, Rodriguez, J G, Kuhn, G R, Weiss, S G, Hilsenbeck, J R, Eckardt, A, Thurman, D A, Rinaldi, S, Hodges, D D, Von Hoff, E K, Rowinsky

Publikováno v: Blood. 91(5)

Despite the widespread usage of hydroxyurea in the treatment of both malignant and nonmalignant diseases and a recent expansion in the recognition of its potential therapeutic applications, there have been few detailed studies of hydroxyurea's pharma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::484f6db19a60b2f10310ceb869d22bc7
https://pubmed.ncbi.nlm.nih.gov/9473217

Zobrazit plný text záznamu

[Comparison of 2 serologic methods for the diagnosis of hydatidosis]

Autor: H M, Arienti, S I, Guignard, D E, Rinaldi, O C, Elbarcha

Publikováno v: Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau. 121(3)

The sera of 176 patients with epidemiologic antecedents or radiologic and clinical signs of hydatidosis were tested by counter-immunoelectrophoresis (CIE) and enzyme-linked immunoassay (ELISA). A semipurified antigen from cysts of human origin were u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::16ef4aae1ccb0ade1fcb850fe66ee576
https://pubmed.ncbi.nlm.nih.gov/8962664

Zobrazit plný text záznamu

A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies

Autor: D W, Shaffer, L S, Smith, H A, Burris, G M, Clark, J R, Eckardt, S M, Fields, G R, Weiss, D A, Rinaldi, K J, Bowen, J G, Kuhn

Publikováno v: Cancer research. 53(24)

Data from an in vitro human tumor-cloning assay suggested synergistic cytotoxicity when etoposide (VP16) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were combined. To explore this potential, we undertook a prospectively randomized t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8101371c0127422ce7b87cd14504fbef
https://pubmed.ncbi.nlm.nih.gov/8261405

Zobrazit plný text záznamu

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Autor: K. J. Brill, D. A. Rinaldi, M. S. Berger, C. A. Henderson, C. J. Germond, L. H. Leopold, A. L. A. Fields, L. Chu

Publikováno v: Journal of Clinical Oncology. 23:3583-3583

3583 Background: Lapatinib is an orally active, reversible inhibitor of the tyrosine kinase activity of ErbB1 (EGFR) and ErbB2 (HER-2/neu). This multicenter, open-label, phase II study was designed to evaluate the safety and efficacy of single-agent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed84c2eb4ece550e1119fe8236808169
https://doi.org/10.1200/jco.2005.23.16_suppl.3583

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání